Hennion & Walsh Asset Management Inc. Purchases Shares of 259,980 Autolus Therapeutics plc (NASDAQ:AUTL)

Hennion & Walsh Asset Management Inc. purchased a new stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 259,980 shares of the company's stock, valued at approximately $611,000. Hennion & Walsh Asset Management Inc. owned approximately 0.10% of Autolus Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock valued at $4,663,000 after purchasing an additional 761,008 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock valued at $87,919,000 after acquiring an additional 6,330,392 shares during the last quarter. State Street Corp grew its position in Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company's stock worth $2,202,000 after acquiring an additional 10,401 shares during the period. HighVista Strategies LLC raised its position in Autolus Therapeutics by 2.7% in the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company's stock valued at $1,935,000 after purchasing an additional 14,204 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Autolus Therapeutics in the 3rd quarter valued at $708,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Stock Down 0.2 %

NASDAQ:AUTL traded down $0.01 on Tuesday, reaching $2.22. 453,222 shares of the company's stock were exchanged, compared to its average volume of 1,064,745. The business has a fifty day moving average of $2.67 and a 200-day moving average of $3.55. Autolus Therapeutics plc has a 52-week low of $2.07 and a 52-week high of $7.37. The firm has a market capitalization of $589.39 million, a price-to-earnings ratio of -1.82 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the business posted ($0.26) EPS. As a group, equities analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Needham & Company LLC restated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price for the company in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.